Journal of Cancer Research and Clinical Oncology

, Volume 130, Issue 1, pp 1–7

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review

Review

DOI: 10.1007/s00432-003-0498-7

Cite this article as:
Swain, S.M. & Vici, P. J Cancer Res Clin Oncol (2004) 130: 1. doi:10.1007/s00432-003-0498-7

Abstract

This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.

Keywords

CancerAnthracyclineDoxorubicinCardiotoxicityDexrazoxane

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.National Institutes of HealthDepartment of Health and Human ServicesBethesdaUSA
  2. 2.2nd Division of Medical OncologyRegina Elena Institute for Cancer ResearchRomeItaly